The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway is frequently activated in many cancers, including prostate cancer where this is often following loss of phosphatase and tensin homolog (PTEN). The CAPItello-281 trial is the first phase III trial to evaluate AKT inhibition added at start of androgen deprivation therapy for metastatic prostate cancer, specifically in combination with abiraterone acetate and…
The Achilles heel of precision AKT-targeted therapies in advanced prostate cancer: therapeutic promise constrained by the test
Annals of Oncology | | Emily Grist, Christopher J. Sweeney, Gerhardt Attard
Topics: prostate-cancer, blood-cancer, clinical-trials, research